ARTICLE | Clinical News
Inovio resumes VGX-3100 HPV cancer program
June 8, 2017 10:46 PM UTC
Inovio Pharmaceuticals Inc. (NASDAQ:INO) gained $0.80 (11%) to $8.19 on Thursday after the company said FDA lifted a clinical hold on its Phase III program of VGX-3100 to treat cervical dysplasia caused by HPV. The company plans to immediately begin a pair of Phase III trials of the candidate.
FDA placed the hold on Inovio’s development program for VGX-3100 last October and requested additional data on the shelf life of the company's redesigned Cellectra electroporation device used to administer the product (see BioCentury Extra, Oct. 24, 2016)...
BCIQ Target Profiles